Group by Gene: Chemotherapy DNA Serine-Threonine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Threonine-Tyrosine Kinase Inhibitors Tyrosine Kinase Inhibitors | DNA synthesis inhibitor temozolomide | BRAF inhibitor dabrafenib | BRAF inhibitor, BRAF V600E inhibitor vemurafenib | PD1 inhibitor nivolumab | TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor larotrectinib | Chemotherapy PCV | PD-L1 inhibitor, MEK1 inhibitor atezolizumab + cobimetinib | Tubulin polymerization promoter, Tubulin polymerization inhibitor, DNA synthesis inhibitor carboplatin + temozolomide + vincristine |
---|---|---|---|---|---|---|---|---|
No biomarker | ||||||||
IDH1 R132H | ||||||||
IDH1 mutation | ||||||||
MGMT promoter methylation | ||||||||
BRAF mutation | ||||||||
BRAF V600 | ||||||||
IDH2 mutation | ||||||||
ABCB1 G412G | ||||||||
TMB-H | ||||||||
NACC2-NTRK2 fusion | ||||||||
NRAS mutation | ||||||||
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation |